BioSyent (CVE:RX) Reaches New 1-Year High – Should You Buy?

BioSyent Inc. (CVE:RX) shares reached a new 52-week high during trading on Monday . The company traded as high as C$12.80 and last traded at C$12.70, with a volume of 3936 shares changing hands. The stock had previously closed at C$12.80.

Analyst Ratings Changes

Separately, Bloom Burton upgraded shares of BioSyent from a “moderate buy” rating to a “strong-buy” rating in a report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

BioSyent Stock Performance

The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The firm has a market cap of C$143.03 million, a PE ratio of 16.98 and a beta of 0.56. The stock’s 50 day moving average price is C$11.49 and its 200 day moving average price is C$11.61.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.